Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holger Weis is CEO at Alaunos Therapeutics. OQRO lists 9 transactions filed with the SEC under this name, the latest on Oct 8, 2026, each linked to the official Form 4.
CEO
Disclosures on record
9
Companies involved
2
Holger Weis bought shares on the open market in 2021, and has not bought since 2021.
Holger Weis reported 1 open-market purchase and 0 sales since 2021; purchases in 2021.
| Year | Bought | Sold |
|---|---|---|
| 2021 | $92K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Alaunos TherapeuticsTCRT
6 disclosures · May 2026 – Oct 2026
Oct 6, 202624Kdisclosed Oct 8
DetailsOfficial recordAug 6, 20264,363disclosed Aug 11
DetailsOfficial recordJul 23, 20264,568disclosed Jul 27
DetailsOfficial recordJun 30, 20263,880disclosed Jul 2
DetailsOfficial recordJun 12, 20267,761disclosed Jun 17
DetailsOfficial recordMay 22, 20263,700disclosed May 27
DetailsOfficial recordJupiter NeurosciencesJUNS
3 disclosures · Jun 2026 – Jul 2026
Jun 2, 202586Kdisclosed Jul 13
DetailsOfficial recordJun 2, 202586Kdisclosed Jul 13
DetailsOfficial recordJun 2, 2026100Kdisclosed Jun 5
DetailsOfficial recordHolger Weis reported 1 open-market purchase and 0 sales here, 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
As of the latest filing on , Holger Weis reported holding 96,581 shares of Jupiter Neurosciences (JUNS), worth about $141K at the last close of $1 (Nov 19, 2026). Holdings are also on file at Alaunos Therapeutics (TCRT); together they are worth about $219K.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Jupiter Neurosciences JUNS | 96,581 | 97K direct | $1 | $141K | Jun 2, 2025 |
| Alaunos Therapeutics TCRT | 49,047 | 49K direct | $2 | $78K | Oct 6, 2026 |
Is this Holger Weis’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jun 2, 2025, Holger Weis reported holding 96,581 shares of Jupiter Neurosciences (JUNS). At the last close of $1 on Nov 19, 2026, that is about $141K. This is the stake disclosed in filings, not a net worth.
No public filing gives Holger Weis's net worth. What SEC Form 4 shows is the stock stake: 96,581 shares of Jupiter Neurosciences (JUNS), about $141K at the last close, plus holdings in 1 other company, about $219K in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Holger Weis bought shares on the open market in 2021, and has not bought since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2021; no open-market sale is on record.
Alaunos Therapeutics (TCRT), from 2021 to 2021: 1 purchase and 0 sales.